NextFin News - Gene Solutions, the Vietnamese biotechnology firm that dominates its domestic genetic testing market, is preparing for a dual-track capital raise targeting $100 million to fuel its expansion across Southeast Asia. The Ho Chi Minh City-based company is currently seeking up to $50 million in a pre-IPO funding round, with plans to raise an additional $50 million through a public listing as early as 2026. According to Chief Financial Officer Keng Hsu, the company is evaluating both Hong Kong and Singapore as potential listing venues, marking a significant step for a Vietnamese startup seeking international capital markets.
The move comes as Gene Solutions attempts to replicate its domestic success—where it held approximately 90% of the non-invasive prenatal testing (NIPT) market in 2021—across a region with fragmented regulatory landscapes. The company, which utilizes next-generation sequencing and artificial intelligence for prenatal and cancer screenings, has already established a presence in Thailand, Indonesia, and the Philippines. However, the transition from a dominant local player to a regional powerhouse requires navigating a complex web of national healthcare policies and varying insurance reimbursement frameworks.
Keng Hsu, who joined the firm with a background in regional finance, has been a vocal proponent of the company’s "asset-light" expansion strategy. Hsu’s perspective, while optimistic about the scalability of the firm’s AI-driven diagnostic platform, represents the internal corporate view and may not fully account for the intensifying competition from global giants like Illumina or regional rivals in China. Market analysts note that while Gene Solutions is profitable—a rarity among early-stage biotech firms—its valuation at IPO will depend heavily on its ability to prove that its low-cost model can maintain margins outside of Vietnam’s relatively low-competition environment.
The choice between Hong Kong and Singapore reflects a broader dilemma for Southeast Asian tech firms. Hong Kong offers deeper liquidity and a specialized chapter for biotech listings, which has historically attracted larger valuations for healthcare companies. Conversely, Singapore provides a familiar regulatory environment for Southeast Asian entities and has been aggressively courting regional tech leaders. The decision will likely hinge on which exchange offers the most favorable environment for a mid-sized biotech firm that is transitioning from venture capital backing, including support from Mekong Capital, to public market scrutiny.
Significant risks remain for the 2026 timeline. The genetic testing industry is highly sensitive to data privacy regulations, which are tightening across ASEAN nations. Furthermore, the success of the IPO is contingent on the continued recovery of the Hong Kong and Singapore capital markets, which have faced periods of volatility and low IPO volumes over the past two years. If regional reimbursement policies for genetic screening do not modernize as quickly as Gene Solutions anticipates, the company may find its growth trajectory constrained by out-of-pocket costs for patients in emerging markets.
Explore more exclusive insights at nextfin.ai.
